Show simple item record

dc.contributor.authorNash, Peter
dc.contributor.authorLim, Irwin
dc.contributor.authorMarabani, Mona
dc.date.accessioned2021-07-05T03:25:45Z
dc.date.available2021-07-05T03:25:45Z
dc.date.issued2021
dc.identifier.issn1756-1841en_US
dc.identifier.doi10.1111/1756-185X.14127en_US
dc.identifier.urihttp://hdl.handle.net/10072/405658
dc.description.abstractThe last decade has seen considerable advancement in the treatment options available to patients with rheumatoid arthritis (RA) through the development of oral, small molecules that target and inhibit Janus kinases (JAKi). These drugs have a rapid onset of action, disrupting the Janus kinase/signal transducer and activator of transcription pathway and preventing the production of cytokines involved in inflammatory processes. They have the potential to provide immunomodulatory benefits across a broad range of diseases. This narrative review focuses on the safety profile of tofacitinib, baricitinib, upadacitinib, and filgotinib. Although JAKi have been shown to be effective in the treatment of RA, it is posited that they have different selectivities, which are likely to affect their safety profiles in RA patients. Currently, there are limited long-term safety data available, with most data coming from randomized controlled trials. However, the data that are available show that upadacitinib and filgotinib may have improved safety profiles. This is particularly true in relation to herpes zoster, venous thromboembolism, and gastrointestinal perforation. Future research is needed to investigate the safety and efficacy of switching between JAKi when a previous JAKi has not been tolerated or has been ineffective.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.relation.ispartofpagefrom3en_US
dc.relation.ispartofpageto14en_US
dc.relation.ispartofissueS1en_US
dc.relation.ispartofjournalInternational Journal of Rheumatic Diseasesen_US
dc.relation.ispartofvolume24en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchImmunologyen_US
dc.subject.fieldofresearchMedical Microbiologyen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.fieldofresearchcode1107en_US
dc.subject.fieldofresearchcode1108en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsRheumatologyen_US
dc.subject.keywordsantirheumatic agentsen_US
dc.subject.keywordsJanus kinase inhibitorsen_US
dc.titleA comparison of Janus kinase inhibitor safety in rheumatoid arthritisen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationNash, P; Lim, I; Marabani, M, A comparison of Janus kinase inhibitor safety in rheumatoid arthritis, International Journal of Rheumatic Diseases, 2021, 24 (S1), pp. 3-14en_US
dc.date.updated2021-07-02T05:34:06Z
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record